$22.03
0.974.61%
At Close: -
$22.03
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Castle Biosciences (NASDAQ:CSTL) Stock, Analyst Ratings, Price Targets, Forecasts
Castle Biosciences Inc has a consensus price target of $35.09 based on the ratings of 11 analysts. The high is $50 issued by SVB Leerink on August 9, 2022. The low is $25 issued by Guggenheim on December 14, 2023. The 3 most-recent analyst ratings were released by Baird, Baird, and Keybanc on July 5, 2024, May 3, 2024, and March 1, 2024, respectively. With an average price target of $32 between Baird, Baird, and Keybanc, there's an implied 45.26% upside for Castle Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
Keybanc
Scotiabank
Guggenheim
Lake Street
1calculated from analyst ratings
Analyst Ratings for Castle Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/05/2024 | Buy Now | 54.33% | Baird | Catherine Ramsey | $34 → $34 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 54.33% | Baird | Catherine Ramsey | $33 → $34 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 27.1% | Keybanc | Paul Knight | $25 → $28 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 67.95% | Scotiabank | Sung Ji Nam | $33 → $37 | Maintains | Sector Outperform | Get Alert |
| 12/14/2023 | Buy Now | 13.48% | Guggenheim | Subbu Nambi | → $25 | Initiates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | 13.48% | Keybanc | Paul Knight | $37 → $25 | Maintains | Overweight | Get Alert |
| 07/07/2023 | Buy Now | 45.26% | Lake Street | Thomas Flaten | → $32 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | 67.95% | Stephens & Co. | Mason Carrico | → $37 | Reiterates | Overweight → Overweight | Get Alert |
| 06/15/2023 | Buy Now | 36.18% | BTIG | Mark Massaro | $38 → $30 | Maintains | Buy | Get Alert |
| 06/07/2023 | Buy Now | 49.8% | Scotiabank | Sung Ji Nam | $54 → $33 | Maintains | Sector Outperform | Get Alert |
| 06/06/2023 | Buy Now | 81.57% | Canaccord Genuity | Kyle Mikson | $60 → $40 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 58.87% | SVB Securities | Puneet Souda | $50 → $35 | Maintains | Outperform | Get Alert |
| 06/05/2023 | Buy Now | 45.26% | Lake Street | Thomas Flaten | $41 → $32 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 13.48% | Baird | Catherine Ramsey | $35 → $25 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | 86.11% | Stephens & Co. | Mason Carrico | → $41 | Reiterates | → Overweight | Get Alert |
| 05/05/2023 | Buy Now | 67.95% | Keybanc | Paul Knight | $40 → $37 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 86.11% | Stephens & Co. | Mason Carrico | → $41 | Reiterates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 58.87% | Baird | Catherine Ramsey | $38 → $35 | Maintains | Outperform | Get Alert |
| 03/02/2023 | Buy Now | 86.11% | Stephens & Co. | Mason Carrico | → $41 | Reiterates | → Overweight | Get Alert |
| 03/01/2023 | Buy Now | 72.49% | Baird | Catherine Schulte | $42 → $38 | Maintains | Outperform | Get Alert |
| 01/05/2023 | Buy Now | 145.12% | Scotiabank | Sung Ji Nam | → $54 | Initiates | → Sector Outperform | Get Alert |
| 11/03/2022 | Buy Now | 86.11% | Baird | Catherine Schulte | $48 → $41 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 117.88% | Baird | Catherine Ramsey | $44 → $48 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 126.96% | SVB Leerink | Puneet Souda | $45 → $50 | Maintains | Market Outperform | Get Alert |
| 05/11/2022 | Buy Now | 81.57% | Keybanc | Paul Knight | $90 → $40 | Maintains | Overweight | Get Alert |
| 05/10/2022 | Buy Now | 99.73% | Baird | Catherine Schulte | $50 → $44 | Maintains | Outperform | Get Alert |
| 05/10/2022 | Buy Now | 104.27% | SVB Leerink | Puneet Souda | $65 → $45 | Maintains | Outperform | Get Alert |
| 04/05/2022 | Buy Now | 263.14% | Canaccord Genuity | Kyle Mikson | $94 → $80 | Maintains | Buy | Get Alert |
| 03/01/2022 | Buy Now | 185.97% | Lake Street | Thomas Flaten | $94 → $63 | Maintains | Buy | Get Alert |
| 01/07/2022 | Buy Now | 167.82% | Stephens & Co. | Mason Carrico | → $59 | Initiates | → Overweight | Get Alert |
| 11/09/2021 | Buy Now | 240.44% | SVB Leerink | Puneet Souda | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Castle Biosciences (CSTL) stock?
The latest price target for Castle Biosciences (NASDAQ:CSTL) was reported by Baird on July 5, 2024. The analyst firm set a price target for $34.00 expecting CSTL to rise to within 12 months (a possible 54.33% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Castle Biosciences (CSTL)?
The latest analyst rating for Castle Biosciences (NASDAQ:CSTL) was provided by Baird, and Castle Biosciences maintained their outperform rating.
When was the last upgrade for Castle Biosciences (CSTL)?
There is no last upgrade for Castle Biosciences
When was the last downgrade for Castle Biosciences (CSTL)?
There is no last downgrade for Castle Biosciences.
When is the next analyst rating going to be posted or updated for Castle Biosciences (CSTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Castle Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Castle Biosciences was filed on July 5, 2024 so you should expect the next rating to be made available sometime around July 5, 2025.
Is the Analyst Rating Castle Biosciences (CSTL) correct?
While ratings are subjective and will change, the latest Castle Biosciences (CSTL) rating was a maintained with a price target of $34.00 to $34.00. The current price Castle Biosciences (CSTL) is trading at is $22.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.